K Stille1, J G Kuipers2, S Herget-Rosenthal3. 1. Medizinische Klinik, Rotes Kreuz Krankenhaus, St. Pauli Deich 24, 28199, Bremen, Deutschland. 2. Klinik für internistische Rheumatologie, Rotes Kreuz Krankenhaus, Bremen, Deutschland. 3. Medizinische Klinik, Rotes Kreuz Krankenhaus, St. Pauli Deich 24, 28199, Bremen, Deutschland. herget-rosenthal.s@roteskreuzkrankenhaus.de.
Abstract
INTRODUCTION: In the MEPEX trial the poor prognosis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis with severe renal manifestation (AAVr) could be significantly improved in the first year by plasmapheresis. How and to what extent is this knowledge of AAVr therapy implemented into routine practice and what effectiveness and adverse events resulted? METHODS: This was a retrospective cohort study in which all patients who received remission induction therapy for AAVr under routine clinical conditions (RCC) in this hospital from 2009 to 2014 after publication of the MEPEX trial (n = 22) were compared with those in the plasmapheresis arm of the MEPEX trial (n = 70). Endpoints were dialysis-dependent chronic kidney disease and mortality after 3 and 12 months and severe life-threatening adverse events during the first 12 months. RESULTS: All patients with AAVr were treated by plasmapheresis under RCC. The two groups showed no differences with respect to the rate of dialysis dependency (after 3 months RCC 14 % versus MEPEX 16 %, P = 1.00 and after 12 months RCC 23 % versus MEPEX 14 %, P = 0.55) or mortality (after 3 months RCC 18 % versus MEPEX 16 %, P = 0.75 and after 12 months RCC 18 % versus MEPEX 27 %, P = 0.57). The rate of severe life-threatening adverse events was similar under RCC and under controlled study conditions (64 % versus 69 %, P = 0.87). CONCLUSION: Under RCC there is a high quality of medical treatment for AAVr. All patients received plasmapheresis for remission induction with comparable effectiveness and safety compared to controlled study conditions.
INTRODUCTION: In the MEPEX trial the poor prognosis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis with severe renal manifestation (AAVr) could be significantly improved in the first year by plasmapheresis. How and to what extent is this knowledge of AAVr therapy implemented into routine practice and what effectiveness and adverse events resulted? METHODS: This was a retrospective cohort study in which all patients who received remission induction therapy for AAVr under routine clinical conditions (RCC) in this hospital from 2009 to 2014 after publication of the MEPEX trial (n = 22) were compared with those in the plasmapheresis arm of the MEPEX trial (n = 70). Endpoints were dialysis-dependent chronic kidney disease and mortality after 3 and 12 months and severe life-threatening adverse events during the first 12 months. RESULTS: All patients with AAVr were treated by plasmapheresis under RCC. The two groups showed no differences with respect to the rate of dialysis dependency (after 3 months RCC 14 % versus MEPEX 16 %, P = 1.00 and after 12 months RCC 23 % versus MEPEX 14 %, P = 0.55) or mortality (after 3 months RCC 18 % versus MEPEX 16 %, P = 0.75 and after 12 months RCC 18 % versus MEPEX 27 %, P = 0.57). The rate of severe life-threatening adverse events was similar under RCC and under controlled study conditions (64 % versus 69 %, P = 0.87). CONCLUSION: Under RCC there is a high quality of medical treatment for AAVr. All patients received plasmapheresis for remission induction with comparable effectiveness and safety compared to controlled study conditions.
Entities:
Keywords:
Antineutrophil cytoplasmic antibody; Dialysis; Health services research; Plasmapheresis; Remission
Authors: Julia U Holle; Wolfgang L Gross; Ute Latza; Bernhard Nölle; Petra Ambrosch; Martin Heller; Regina Fertmann; Eva Reinhold-Keller Journal: Arthritis Rheum Date: 2011-01
Authors: Oliver Flossmann; Annelies Berden; Kirsten de Groot; Chris Hagen; Lorraine Harper; Caroline Heijl; Peter Höglund; David Jayne; Raashid Luqmani; Alfred Mahr; Chetan Mukhtyar; Charles Pusey; Niels Rasmussen; Coen Stegeman; Michael Walsh; Kerstin Westman Journal: Ann Rheum Dis Date: 2010-11-24 Impact factor: 19.103
Authors: David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey Journal: N Engl J Med Date: 2003-07-03 Impact factor: 91.245
Authors: Michael Walsh; Alina Casian; Oliver Flossmann; Kerstin Westman; Peter Höglund; Charles Pusey; David R W Jayne Journal: Kidney Int Date: 2013-04-24 Impact factor: 10.612
Authors: Z Hruskova; A L Casian; P Konopasek; B Svobodova; D Frausova; V Lanska; V Tesar; D R W Jayne Journal: Scand J Rheumatol Date: 2013-02-04 Impact factor: 3.641
Authors: David R W Jayne; Gill Gaskin; Niels Rasmussen; Daniel Abramowicz; Franco Ferrario; Loic Guillevin; Eduardo Mirapeix; Caroline O S Savage; Renato A Sinico; Coen A Stegeman; Kerstin W Westman; Fokko J van der Woude; Robert A F de Lind van Wijngaarden; Charles D Pusey Journal: J Am Soc Nephrol Date: 2007-06-20 Impact factor: 10.121
Authors: Michael Walsh; Peter A Merkel; Chen Au Peh; Wladimir Szpirt; Loïc Guillevin; Charles D Pusey; Janak De Zoysa; Natalie Ives; William F Clark; Karen Quillen; Jeffrey L Winters; Keith Wheatley; David Jayne Journal: Trials Date: 2013-03-14 Impact factor: 2.279